Upstate Active Clinical Trials
Study Title:A 12-month, randomized, rater- and dose-blinded study to compare the efficacy and safety of fingolimod 0.25 mg and 0.5 mg administered orally once daily with glatiramer acetate 20 mg administered subcutaneously once daily in patients with relapsing-remitting multiple sclerosis
What is the purpose of the study?Compare 2 doses of fingolimod to copaxone and to evaluate the efficacy and safety of fingolimod for the treatment of patients with relapsing-remitting Multiple Sclerosis
Upstate Institutional Review Board (IRB) Number:345511
Patient Age Group:Adults
Principal Investigator:Burk Jubelt, MD
What is involved if I participate?
- How long is the study?
- Is transportation provided or reimbursed?
- Is parking provided or reimbursed?
- What tests and procedures are involved?
MRI, Neurological assessments and safety assessments.
Where will the study take place?Institute for Human Performance
Who can I contact for more information?
Name: Courtney Goodrich